// App-Quantinova.ai

1821 : Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study

Researchers

Presenter

  • Tsutomu Takeuchi

Principal Investigators

  • Mark C. Genovese

  • Boulos Haraoui

  • Zhanguo Li

  • Li Xie

  • Rena Klar

  • Ana Pinto Correia

  • Susan Otawa

  • Pedro Lopez-Romero

  • Inmaculada de la Torre

  • Terence P. Rooney

  • Josef S. Smolen

Medical Centers

  • Stanford University Medical Center, Palo Alto, CA

  • Institut de Rhumatologie, Montreal, QC, Canada

  • Peking University People's Hospital, Beijing, China

  • Eli Lilly and Company, Indianapolis, IN

  • Quintiles IMS Holdings, Inc., Durham, NC

  • Europe Research Center, Eli Lilly and Company, Madrid, Spain

  • Medical University of Vienna, Vienna, Austria

Locations

  • Japan

  • United States

  • Canada

  • China

  • Spain

  • Austria

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved